Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
ContraFect Corp. is a biotechnology company focused on developing innovative therapies for serious bacterial infections, particularly those caused by antibiotic-resistant pathogens. Its lead product candidate, CF-301, is designed to treat Staphylococcus aureus infections, which presents a significant market opportunity given the rising prevalence of antibiotic resistance.
ContraFect is primarily in the research and development phase, focusing on the development of CF-301 and other therapeutic candidates. Revenue generation is expected to commence upon successful clinical trials and subsequent commercialization. The company has a unique position in targeting antibiotic-resistant infections, which are a growing public health concern.
Progress in clinical trials for CF-301, particularly Phase 3 results
Partnership announcements or collaborations with larger pharmaceutical companies
Regulatory approvals from the FDA or EMA for CF-301
Market sentiment regarding antibiotic resistance and public health initiatives
Regulatory changes affecting drug approval processes
Technological disruption in antibiotic development
Emergence of alternative therapies for bacterial infections
Competitive pressures from larger biotech firms with more resources
High cash burn rate with limited revenue generation
Potential dilution from future capital raises
low - The demand for biopharmaceuticals is less sensitive to economic cycles, as healthcare needs persist regardless of economic conditions.
Moderate - Higher interest rates could increase the cost of capital for funding clinical trials, impacting the company's financial flexibility.
minimal - The company has a negative debt/equity ratio, indicating limited reliance on external financing.
growth - Investors looking for high-risk, high-reward opportunities in biotech will be attracted to ContraFect's innovative approach.
high - The stock is likely to exhibit high volatility due to clinical trial outcomes and market sentiment.
